SCHEMBL1186172

SCHEMBL1186172

Oc1ccc(-c2cocn2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 4/20 0.46
MAPT P10636 3/20 0.45
ALDH1A1 P00352 1/20 0.45
POLB P06746 1/20 0.45
HPGD P15428 1/20 0.45
HSD17B10 Q99714 1/20 0.45
HDAC4 P56524 1/20 0.44
ESR2 Q92731 2/20 0.42
BCHE P06276 1/20 0.40
NAAA Q02083 1/20 0.40
MEN1 O00255 7/20 0.39
KMT2A Q03164 7/20 0.39
NPC1 O15118 3/20 0.39
RAB9A P51151 3/20 0.39
USP2 O75604 1/20 0.39
TP53 P04637 1/20 0.39
PKM P14618 1/20 0.39
NFKB1 P19838 1/20 0.39
NFKB2 Q00653 1/20 0.39
RELA Q04206 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8007463 0.84 ESR1 (0.57) ESR1MAPTALDH1A1POLBHPGD
SCHEMBL5836419 0.78 SCN9A (0.43) ALDH1A1HDAC4MEN1KMT2ANPC1
SCHEMBL1646055 0.78 HDAC4 (0.44) MAPTALDH1A1HPGDHSD17B10HDAC4
SCHEMBL9288053 0.78 ENPP3 (0.47) MAPTALDH1A1POLBHPGDHDAC4
SCHEMBL5999068 0.78 HDAC4 (0.44) MAPTALDH1A1POLBHPGDHSD17B10
SCHEMBL16058716 0.78 NAAA (0.43) HDAC4NAAASCN9AMKNK1MKNK2
SCHEMBL4751198 0.76 HSD17B1 (0.58) SCN9AHSD17B1HSD17B2
SCHEMBL4765377 0.76 HDAC4 (0.50) ALDH1A1POLBHPGDHDAC4NPC1
SCHEMBL3193030 0.76 LMNA (0.43) MAPTHDAC4NAAANPC1RAB9A
SCHEMBL1655655 0.75 P4HA1 (0.32) ESR1HDAC4SCN9AHSD17B1HSD17B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6890923-B2 Compounds ASTRAZENECA AB (SE) 2005-05-10 US claimed
US-20040122028-A1 Novel compounds ASTRAZENECA AB (SE) 2004-06-24 US claimed
WO-2025106362-A1 RIPK1 INHIBITORS AND METHODS OF USE MERCK SHARP & DOHME LLC (US) 2025-05-22 WO disclosed
WO-2025070747-A1 METHOD FOR MEASURING ANTIGEN CONTAINED IN TEST SAMPLE, AND KIT FOR MEASURING HUMAN CHORIONIC GONADOTROPIN OR ESTRADIOL 富士フイルム株式会社 2025-04-03 WO disclosed
EP-4325210-A1 COMPOSITION, STABILIZATION METHOD, METHOD FOR MEASURING AMOUNT OF LUMINESCENCE, AND STABILIZER FOR LUMINESCENT SUBSTRATE FUJIFILM Corporation (JP) 2024-02-21 EP disclosed
US-20240043742-A1 COMPOSITION, STABILIZATION METHOD, METHOD FOR MEASURING AMOUNT OF LUMINESCENCE, AND STABILIZER FOR LUMINESCENT SUBSTRATE FUJIFILM CORPORATION (JP) 2024-02-08 US disclosed
WO-2022220288-A1 COMPOSITION, STABILIZATION METHOD, METHOD FOR MEASURING AMOUNT OF LUMINESCENCE, AND STABILIZER FOR LUMINESCENT SUBSTRATE 富士フイルム株式会社 2022-10-20 WO disclosed
EP-3366750-B1 STABILIZER AND STABILIZATION METHOD FUJIFILM WAKO PURE CHEMICAL CORP (JP) 2021-07-21 EP disclosed
US-10961185-B2 Stabilizer and stabilization method FUJIFILM WAKO PURE CHEMICAL CHEMICAL CORPORATION (JP) 2021-03-30 US disclosed
CN-108138047-B Stabilizer and stabilization method 富士胶片和光纯药株式会社 2021-02-09 CN disclosed
CN-105315319-B Hepatitis C virus inhibitor and application thereof 南京圣和药业股份有限公司 2020-11-20 CN disclosed
US-20030166686-A1 Beta3 adrenergic receptor agonist crystal forms, processes for the production thereof, and uses thereof PFIZER INC. 2003-09-04 US disclosed
WO-2003072573-A1 CRYSTAL FORMS OF (R)-2-(2-(4-OXAZOL-4-YL-PHENOXY)-ETHYLAMINO)-1-PYRIDIN-3-YL-ETHANOL PFIZER PRODUCTS INC. (US) 2003-09-04 WO disclosed
EP-0384271-B1 Method for enhancement of chemiluminescence WAKO PURE CHEM IND LTD (JP) 1996-05-08 EP disclosed
US-5106732-A Using oxazole or thiazole derivative TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1992-04-21 US disclosed
US-5002960-A Viricides for combating picornaviruses STERLING DRUG, INC. (US) 1991-03-26 US disclosed
EP-0384271-A2 Method for enhancement of chemiluminescence WAKO PURE CHEMICAL INDUSTRIES LTD (JP) 1990-08-29 EP disclosed
US-4939267-A Viricides STERLING DRUG INC. (US) 1990-07-03 US disclosed
US-4843087-A OXAZOLINYL COMPOUNDS; RHINOVIRUSES AND PICORNAVIRUSES STERLING DRUG INC. (US) 1989-06-27 US disclosed
US-4005201-A DIURETICS TAKEDA CHEMICAL INDUSTRIES, LTD. (JA) 1977-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10961185-B2 Stabilizer and stabilization method H1-0, H1-2, H1-4 ESR1 3595/4885MAPT 2821/4885ALDH1A1 993/4885
US-20040122028-A1 Novel compounds DPYD, TYMS, TYMP ESR1 3579/4885MAPT 4073/4885ALDH1A1 284/4885
US-20030166686-A1 Beta3 adrenergic receptor agonist crystal forms, processes for the production thereof, and uses thereof ADRB3, ADRB1, ADRB2 ESR1 2546/4885MAPT 1416/4885ALDH1A1 1882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.